Affordable Access

deepdyve-link
Publisher Website

Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway.

Authors
  • Higgs, Brandon W
  • Liu, Zheng
  • White, Barbara
  • Zhu, Wei
  • White, Wendy I
  • Morehouse, Chris
  • Brohawn, Philip
  • Kiener, Peter A
  • Richman, Laura
  • Fiorentino, David
  • Greenberg, Steven A
  • Jallal, Bahija
  • Yao, Yihong
Type
Published Article
Journal
Annals of the Rheumatic Diseases
Publisher
BMJ
Publication Date
Nov 01, 2011
Volume
70
Issue
11
Pages
2029–2036
Identifiers
DOI: 10.1136/ard.2011.150326
PMID: 21803750
Source
Medline
License
Unknown

Abstract

The results indicate that the type I IFN pathway is activated in patient subsets of five rheumatic diseases and suggest that these subsets may benefit from anti-IFN therapy.

Report this publication

Statistics

Seen <100 times